Abstract:Histone deacetylase 6 (HDAC6) has been shown to be involved in various pathological conditions, including cancer, neurodegenerative disorders and inflammatory diseases. Nonetheless, its specific role in drug-induced nephrotoxicity is poorly understood. Cisplatin (dichlorodiamino platinum) belongs to an inorganic platinum - fundamental chemotherapeutic drug utilized in the therapy of various solid malignant tumors. However, the use of cisplatin is extremely limited by obvious side effects, for instance bone marrow suppression and nephrotoxicity. In the present study, we utilized a murine model of cisplatin-induced acute kidney injury (AKI) and a highly selective inhibitor of HDAC6, tubastatin A (TA), to assess the role of HDAC6 in nephrotoxicity and its associated mechanisms. Cisplatin-induced AKI was accompanied by increased expression and activation of HDAC6; blocking HDAC6 with TA lessened renal dysfunction, attenuated renal pathological changes, reduced expression of neutrophil gelatinase-associated lipocalin and kidney injury molecule 1, and decreased tubular cell apoptosis. In cultured human epithelial cells, TA or HDAC6 siRNA treatment also inhibited cisplatin-induced apoptosis. Mechanistic studies demonstrated that cisplatin treatment induced phosphorylation of AKT and loss of E-cadherin in the nephrotoxic kidney, and administration of TA enhanced AKT phosphorylation and preserved E-cadherin expression. HDAC6 inhibition also potentiated autophagy as evidenced by increased expression of autophagy-related gene (Atg) 7 (Atg7), Beclin-1, and decreased renal oxidative stress as demonstrated by up-regulation of superoxide dismutase (SOD) activity and down-regulation of malondialdehyde levels. Moreover, TA was effective in inhibiting nuclear factor-kappa B (NF-kappa B) phosphorylation and suppressing the expression of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6). Collectively, these data provide strong evidence that HDAC6 inhibition is protective against cisplatin-induced AKI and suggest that HDAC6 may be a potential therapeutic target for AKI treatment.

HDAC6 Inhibition Alleviates Ischemia- and Cisplatin-Induced Acute Kidney Injury by Promoting Autophagy

Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury.

Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury.

2-Methylquinazoline Derivative 23BB As a Highly Selective Histone Deacetylase 6 Inhibitor Alleviated Cisplatin-Induced Acute Kidney Injury.

Inhibition of HDAC6 with CAY10603 Alleviates Acute and Chronic Kidney Injury by Suppressing the ATF6 Branch of UPR

Histone Deacetylase Inhibitors Protect Against Cisplatin-Induced Acute Kidney Injury by Activating Autophagy in Proximal Tubular Cells.

Inhibition of HDAC6 Activity in Kidney Diseases: a New Perspective

Degradation of histone deacetylase 6 alleviates ROS-mediated apoptosis in renal ischemia-reperfusion injury

Involvement of HDAC6 in Ischaemia and Reperfusion-Induced Rat Retinal Injury

Inhibition of HDAC8 mitigates AKI by reducing DNA damage and promoting homologous recombination repair

HDAC6 inhibition: a significant potential regulator and therapeutic option to translate into clinical practice in renal transplantation

Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF- and EGFR signaling pathways in obstructive nephropathy

Class IIa histone deacetylase inhibition ameliorates acute kidney injury by suppressing renal tubular cell apoptosis and enhancing autophagy and proliferation

Histone deacetylase 6 deficiency protects the liver against ischemia/reperfusion injury by activating PI3K/AKT/mTOR signaling

Polydatin Attenuates Cisplatin-Induced Acute Kidney Injury via SIRT6-Mediated Autophagy Activation

Selective Histone Deacetylase 6 Inhibitor 23BB Alleviated Rhabdomyolysis-Induced Acute Kidney Injury by Regulating Endoplasmic Reticulum Stress and Apoptosis.

Inhibition of HDAC6 With CAY10603 Ameliorates Diabetic Kidney Disease by Suppressing NLRP3 Inflammasome

HDAC6 Inhibition Protects Cardiomyocytes Against Doxorubicin-Induced Acute Damage by Improving Α-Tubulin Acetylation.

Inhibition of HDAC6 Increases Acetylation of Peroxiredoxin1/2 and Ameliorates 6-OHDA Induced Dopaminergic Injury

Overexpressed SIRT6 Attenuates Cisplatin-Induced Acute Kidney Injury by Inhibiting ERK1/2 Signaling

Histone deacetylase 6 inhibition restores autophagic flux to promote functional recovery after spinal cord injury